Hematologic Malignancy
Plasma Cell Neoplasm
CI-CAN-00006438Explore in graph →
HematologicNon-malignant831 active trials25 approved drugs26 evidence items
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00006438Explore in graph →
Clinical trials
3,422 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01272466 | Vaccination With Peptides From Anti-apoptotic Proteins in Relapsed Multiple Myeloma | completed | Phase 1 / Phase 2 | 40 | Herlev HospitalOTHER | 1 | Aug 31, 2018 | clinicaltrials |
| NCT01908621 | Randomized Trial of G-CSF Alone Versus Intermediate-dose Ara-C Plus G-CSF Mobilization in Multiple Myeloma Patients. | completed | Phase 3 | 90 | Maria Sklodowska-Curie National Research Institute of OncologyOTHER | 1 | Aug 28, 2018 |
| NCT01794039 | Pomalidomide or Lenalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide | completed | Phase 2 | 9 | Mayo ClinicOTHER | 1 | Aug 21, 2018 | clinicaltrials |
| NCT03638232 | Myeloma Treatment in Real Life | completed | — | 236 | University Hospital, ToulouseOTHER | 0 | Aug 20, 2018 | clinicaltrials |
| NCT01852799 | A Study of PAD Followed by Autologous Stem Cell Transplantation (ASCT) to Treat Newly Diagnosed Multiple Myeloma | completed | Phase 2 | 18 | Shanghai Changzheng HospitalOTHER | 1 | Aug 10, 2018 | clinicaltrials |
| NCT00064337 | S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis | completed | Phase 2 | 104 | SWOG Cancer Research NetworkNETWORK | 1 | Aug 9, 2018 | clinicaltrials |
| NCT00701103 | Dose Escalation Trial of Dalotuzumab (MK-0646) in Advanced Solid Tumors and Multiple Myeloma (MK-0646-001) | completed | Phase 1 | 80 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 8, 2018 | clinicaltrials |
| NCT01428492 | Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma(PKB115125) | completed | Phase 1 | 90 | NovartisINDUSTRY | 5 | Aug 8, 2018 | clinicaltrials |
| NCT01690143 | Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation | completed | Phase 1 / Phase 2 | 45 | University of Alabama at BirminghamOTHER | 1 | Aug 7, 2018 | clinicaltrials |
| NCT00232934 | Melphalan, Prednisone and Thalidomide Versus Melphalan and Prednisone in Elderly Myeloma Patients | completed | Phase 3 | 400 | Gruppo Italiano per lo Studio del Mieloma MultiploOTHER | 1 | Aug 2, 2018 | clinicaltrials |
| NCT02206503 | Cyclophosphamide With Biochemical Progression During Lenalidomide-Dexamethasone Treatment for Relapsed/Refractory Multiple Myeloma (MM) | completed | Phase 2 | 13 | Fondazione EMN Italy OnlusOTHER | 1 | Aug 2, 2018 | clinicaltrials |
| NCT02331368 | Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma | completed | Phase 2 | 32 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jul 27, 2018 | clinicaltrials |
| NCT01484015 | Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia | completed | Phase 1 | 70 | Wake Forest University Health SciencesOTHER | 1 | Jul 18, 2018 | clinicaltrials |
| NCT02071888 | Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors | completed | Phase 1 | 25 | Calithera Biosciences, IncINDUSTRY | 1 | Jul 18, 2018 | clinicaltrials |
| NCT00001830 | Donor Th2 Cells to Prevent Graft-Versus-Host Disease in Bone Marrow Transplants | completed | Phase 1 | 110 | National Cancer Institute (NCI)NIH | 1 | Jul 5, 2018 | clinicaltrials |
| NCT01526694 | Phase II Trial Designed to Determine Efficacy and Safety of Bendamustine+Dexamethasone+Thalidomide in R/R MM | completed | Phase 2 | 30 | Azienda Ospedaliera di BolzanoOTHER | 1 | Jul 3, 2018 | clinicaltrials |
| NCT01053494 | Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer | completed | N/A | 80 | Wake Forest University Health SciencesOTHER | 1 | Jul 2, 2018 | clinicaltrials |
| NCT01050790 | Lenalidomide + Azacitidine for Adaptive Immunotherapy -> Auto SCT in Multiple Myeloma | completed | N/A | 17 | Virginia Commonwealth UniversityOTHER | 1 | Jun 26, 2018 | clinicaltrials |
| NCT01985126 | An Efficacy and Safety Study of Daratumumab in Patients With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor [PI] and Immunomodulatory Drug [IMiD]) or Are Double Refractory to a PI and an IMiD | completed | Phase 2 | 124 | Janssen Research & Development, LLCINDUSTRY | 3 | Jun 25, 2018 | clinicaltrials |
| NCT03068637 | Integrating Touchscreen-based Geriatric Assessment and Frailty Screening for Adults With Multiple Myeloma | completed | N/A | 165 | Carevive Systems, Inc.INDUSTRY | 1 | Jun 15, 2018 | clinicaltrials |
| NCT00911105 | Non -Interventional Study-Palliative Therapy of Multiple Myeloma With a Combination of Lenalidomide and Dexamethasone(REVLIMID-NIS) | completed | — | 101 | iOMEDICO AGINDUSTRY | 1 | Jun 6, 2018 | clinicaltrials |
| NCT01129193 | AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma | completed | Phase 1 | 44 | Amir MortazaviOTHER | 1 | Jun 4, 2018 | clinicaltrials |
| NCT02203825 | Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands | completed | Phase 1 | 12 | Celyad Oncology SAINDUSTRY | 1 | Jun 1, 2018 | clinicaltrials |
| NCT01936090 | Bortezomib, Melphalan, and Total-Body Irradiation Before Stem Cell Transplant in Treating Patients With Multiple Myeloma | completed | Phase 1 | 11 | Mayo ClinicOTHER | 1 | May 24, 2018 | clinicaltrials |
| NCT02608515 | A Retrospective Chart Review Study of the Outcomes of 2nd Line Therapy With LEn/Dex in Greek Patients With R/R Multiple MyEloma and the Treatment PatterNs Following Progressive Disease(LEGEND) | completed | — | 207 | Genesis Pharma S.A.INDUSTRY | 1 | May 22, 2018 | clinicaltrials |
| NCT01478048 | Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma | completed | Phase 2 | 185 | Bristol-Myers SquibbINDUSTRY | 5 | May 21, 2018 | clinicaltrials |
| NCT01215344 | First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With Velcade | completed | Phase 2 | 36 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | May 15, 2018 | clinicaltrials |
| NCT00884312 | A Study of Extended Carfilzomib Therapy for Patients Previously Enrolled in Carfilzomib Treatment Protocols | completed | Phase 2 | 101 | AmgenINDUSTRY | 2 | May 14, 2018 | clinicaltrials |
| NCT01711528 | Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma | completed | Phase 1 | 41 | National Cancer Institute (NCI)NIH | 1 | May 11, 2018 | clinicaltrials |
| NCT01314963 | Efficacy of Gamma Camera Used Intraoperatively for ID of Sentinel Lymph Nodes w/ Lymphoscintigraphy | completed | N/A | 50 | Stanford UniversityOTHER | 1 | Apr 30, 2018 | clinicaltrials |
| NCT00574288 | Daratumumab (HuMax®-CD38) Safety Study in Multiple Myeloma | completed | Phase 2 | 104 | Janssen Research & Development, LLCINDUSTRY | 4 | Apr 27, 2018 | clinicaltrials |
| NCT00952237 | Immune Mobilization of Autologous Peripheral Blood Stem Cells Using Interleukin-2 and GM-CSF | completed | Phase 1 | 13 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Apr 25, 2018 | clinicaltrials |
| NCT01651039 | Phase II, Single-Center, Oral Panobinostat in Combination With Lenalidomide and Dexamethasone in Multiple Myeloma (MM) | completed | Phase 2 | 32 | Ajai ChariOTHER | 1 | Apr 9, 2018 | clinicaltrials |
| NCT01410981 | Prognostic Potential of Cell Surface Markers and Pim Kinases in Multiple Myeloma | completed | — | 73 | Medical University of South CarolinaOTHER | 1 | Apr 5, 2018 | clinicaltrials |
| NCT02791373 | Vinorelbine and Gemcitabine in Myeloma(ViGeM) | completed | Phase 2 | 136 | Insel Gruppe AG, University Hospital BernOTHER | 1 | Apr 3, 2018 | clinicaltrials |
| NCT01855698 | PENELOPE Observational Study: Prophylaxis and Treatment of Arterial and Venous Thromboembolism | completed | — | 99 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Mar 22, 2018 | clinicaltrials |
| NCT00325416 | Study of Melphalan and Topotecan (MT) Followed by Autologous Stem Cell Rescue in Patients With Multiple Myeloma. | completed | Phase 1 / Phase 2 | 177 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 14, 2018 | clinicaltrials |
| NCT01217957 | A Study of Ixazomib Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma | completed | Phase 1 / Phase 2 | 65 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 14, 2018 | clinicaltrials |
| NCT01547806 | Collection of Transplant Stem Cells for Plasma Cell Myeloma | completed | Phase 2 | 49 | National Cancer Institute (NCI)NIH | 1 | Mar 7, 2018 | clinicaltrials |
| NCT01365559 | Study of Carfilzomib for Multiple Myeloma Patients Who Are Relapsed/Refractory to Bortezomib-containing Treatments | completed | Phase 1 / Phase 2 | 39 | OncotherapeuticsINDUSTRY | 1 | Mar 5, 2018 | clinicaltrials |
| NCT01697839 | Serum Vitamin D Levels and Peripheral Neuropathy Among Multiple Myeloma Patients | completed | — | 110 | OncotherapeuticsINDUSTRY | 1 | Mar 5, 2018 | clinicaltrials |
| NCT00287872 | Bortezomib and Thalidomide in Treating Patients With Newly Diagnosed Stage II or Stage III Multiple Myeloma | completed | Phase 2 | 30 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Mar 1, 2018 | clinicaltrials |
| NCT00375791 | Efficacy of Perifosine Alone and in Combination With Dexamethasone for Patients With Multiple Myeloma | completed | Phase 2 | 67 | AEterna ZentarisINDUSTRY | 1 | Feb 28, 2018 | clinicaltrials |
| NCT02033928 | Comprehensive Frailty Assessment | completed | — | 111 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Feb 28, 2018 | clinicaltrials |
| NCT00401011 | Safety & Efficacy Study of Perifosine + Bortezomib +/- Dexamethasone for Multiple Myeloma Patients | completed | Phase 1 / Phase 2 | 84 | AEterna ZentarisINDUSTRY | 0 | Feb 23, 2018 | clinicaltrials |
| NCT00400686 | Epoetin Alfa in Treating Anemia in Patients Undergoing Chemotherapy for Multiple Myeloma | completed | N/A | 31 | The Cleveland ClinicOTHER | 1 | Feb 22, 2018 | clinicaltrials |
| NCT01241292 | Japanese Study of BMS-901608 (Elotuzumab) in Combination With Lenalidomide and Low Dose Dexamethasone | completed | Phase 1 | 7 | Bristol-Myers SquibbINDUSTRY | 1 | Feb 15, 2018 | clinicaltrials |
| NCT00639002 | A Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424) in Patients With Multiple Myeloma | completed | Phase 2 | 13 | Incyte CorporationINDUSTRY | 1 | Feb 13, 2018 | clinicaltrials |
| NCT01335685 | Study of Oral Ixazomib in Combination With Melphalan and Prednisone in Participants With Newly Diagnosed Multiple Myeloma | completed | Phase 1 / Phase 2 | 61 | Millennium Pharmaceuticals, Inc.INDUSTRY | 5 | Jan 23, 2018 | clinicaltrials |
| NCT01441973 | Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma | completed | Phase 2 | 41 | Bristol-Myers SquibbINDUSTRY | 1 | Jan 23, 2018 | clinicaltrials |
Data updated 24 days agoSource updated Aug 31, 2018source: clinicaltrials